Clinical Trials Logo

Clinical Trial Summary

This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with interstitial lung disease (ILD)-related cough.


Clinical Trial Description

This is a randomized, double-blind, placebo-controlled, parallel-arm, dose escalation study of Duloxetine & Amitriptyline in subjects with interstitial lung disease-related chronic cough. Subjects will be screened during a period of up to 2 week and will undergo screening/ baseline cough monitoring. A total of 25 subjects who meet entry criteria will be randomly assigned in a 1: 1: 1: 1: 1 ratio to one of five treatment arms using stratified randomization in blocks of 5. Each arm will have two successive 4-week treatment periods (Blinded Period 1 & 2). After this, patients will be unblinded and receive routine clinical care. During the unblinded (routine clinical care) follow up phase; subjects will be initially offered the option of continuing amitriptyline or duloxetine based on their initial randomization arm. Subjects could also choose an alternative chronic cough therapy (e.g. pregabalin, gabapentin, 1% tetracaine lollipop or nebulized lidocaine or combination therapy). Subjects in treatment arm 5, who received placebo during the 8 weeks blinded period will have a discussion regarding all available cough therapies. Patients will be offered the flexibility of therapy options during the unblinded follow up as they would during routine clinical care. Participation in the unblinded follow-up period will be optional. Treatment Arm 1: Blinded Period 1 (1st 4 weeks): 30mg of Duloxetine Blinded Period 2 (2nd 4 weeks): 30mg of Duloxetine & 30mg of Placebo Unblinded (routine clinical care) follow up period: (up to 52 weeks): Subjects will be offered routine clinical care management for their chronic cough Treatment Arm 2: Blinded Period 1 (1st 4 weeks): 30mg of Duloxetine Blinded Period 2 (2nd 4 weeks): 60mg of Duloxetine (2 pills of 30mg each) Unblinded (routine clinical care) follow up period: (up to 52 weeks): Subjects will be offered routine clinical care management for their chronic cough Treatment Arm 3: Blinded Period 1 (1st 4 weeks): 25mg of Amitriptyline Blinded Period 2 (2nd 4 weeks): 25mg of Amitriptyline + 25mg of Placebo Unblinded (routine clinical care) follow up period: (up to 52 weeks): Subjects will be offered routine clinical care management for their chronic cough Treatment Arm 4: Blinded Period 1 (1st 4 weeks): 25mg of Amitriptyline Blinded Period 2 (2nd 4 weeks): 50mg of Amitriptyline (2 pills of 25mg each) Unblinded (routine clinical care) follow up period: (up to 52 weeks): Subjects will be offered routine clinical care management for their chronic cough Treatment Arm 5: Blinded Period 1 (1st 4 weeks): 30mg of Placebo Blinded Period 2 (2nd 4 weeks): 60mg of Placebo (2 pills of 30mg each) Unblinded (routine clinical care) follow up period: (up to 52 weeks): Subjects will be offered routine clinical care management for their chronic cough ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05120934
Study type Interventional
Source Mayo Clinic
Contact
Status Recruiting
Phase Phase 2
Start date November 1, 2021
Completion date December 30, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04930289 - Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
Not yet recruiting NCT04089826 - Long Term Oxygen Therapy in Patients With Interstitial Lung Disease
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02633293 - An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE Phase 2/Phase 3
Completed NCT00883129 - Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) Phase 2
Completed NCT00362739 - Blood Collection From Individuals With Lung Disease for Genetic Studies N/A
Recruiting NCT03485378 - Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease N/A
Recruiting NCT04098094 - Outcomes of RV Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases
Recruiting NCT03400839 - Best Clinical Endpoints That Likely Induce Worse Prognosis in Interstitial Lung Diseases
Recruiting NCT05068869 - Digital Outpatient Services N/A
Recruiting NCT03727568 - Study Comparing Two Different Methods of Cryobiopsy in the Interstitial Lung Diseases N/A
Not yet recruiting NCT03800017 - Skeletal Muscle Function in Interstitial Lung Disease N/A
Recruiting NCT04946708 - Virtual Exercise Program in Interstitial Lung Disease (ILD) Patients N/A
Not yet recruiting NCT04481074 - Inspiratory Muscle Training in Patients With Interstitial Lung Disease N/A
Recruiting NCT04139356 - The Effect of Spontaneous Respiration on Pulse-oximetry Measurements N/A
Recruiting NCT03726398 - CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH Phase 2/Phase 3
Recruiting NCT04676594 - Genentech Validation Tool for Pulmonary Fibrosis
Completed NCT02636452 - Cardiopulmonary Exercise Testing in Interstitial Lung Disease
Recruiting NCT04061356 - Assessment of Exhaled Breath Condensate Hydrogen Peroxide (EBC H2O2) as Measured Using a New Device (Inflammacheck™) in Patients With Interstitial Lung Disease, Lung Cancer and Healthy Volunteers.
Recruiting NCT03099525 - Treatment Outcome and Prognostic Factors for Rheumatoid Arthritis (RA) Patients With Interstitial Lung Disease (ILD)